Leukemia - Table of Contents alert Volume 29 Issue 3

TABLE OF CONTENTS Volume 29, Issue 3 (March 2015) In this issue Review Original Articles Letters to the Editor Corrigendum Also new AOP REVIEW You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia A R Sehgal, H Konig, D E Johnson, D Tang, R K Amaravadi, M Boyiadzis and M T Lotze Leukemia 2015 29: 517-525; advance online publication, November 26, 2014; 10.1038/leu.2014.349 Abstract | Full Text ORIGINAL ARTICLES ACUTE LEUKEMIAS Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia OPEN D J DeAngelo, K E Stevenson, S E Dahlberg, L B Silverman, S Couban, J G Supko, P C Amrein, K K Ballen, M D Seftel, A R Turner, B Leber, K Howson-Jan, K Kelly, S Cohen, J H Matthews, L Savoie, M Wadleigh, L A Sirulnik, I Galinsky, D S Neuberg, S E Sallan and R M Stone Leukemia 2015 29: 526-534; advance online publication, July 31, 2014; 10.1038/leu.2014.229 Abstract | Full Text NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia D Gerloff, R Grundler, A A Wurm, D Bräuer-Hartmann, C Katzerke, J-U Hartmann, V Madan, C Müller-Tidow, J Duyster, D G Tenen, D Niederwieser and G Behre Leukemia 2015 29: 535-547; advance online publication, August 5, 2014; 10.1038/leu.2014.231 Abstract | Full Text Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort study L S G Østgård, J M Nørgaard, H Sengeløv, M Severinsen, L S Friis, C W Marcher, I H Dufva and M Nørgaard Leukemia 2015 29: 548-555; advance online publication, August 5, 2014; 10.1038/leu.2014.234 Abstract | Full Text Augmented efficacy with the combination of blockade of the Notch-1 pathway, bortezomib and romidepsin in a murine MT-1 adult T-cell leukemia model P Yu, M N Petrus, W Ju, M Zhang, K C Conlon, M Nakagawa, M Maeda, R N Bamford and T A Waldmann Leukemia 2015 29: 556-566; advance online publication, August 14, 2014; 10.1038/leu.2014.241 Abstract | Full Text Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia C Niederwieser, J Kohlschmidt, S Volinia, S P Whitman, K H Metzeler, A-K Eisfeld, K Maharry, P Yan, D Frankhouser, H Becker, S Schwind, A J Carroll, D Nicolet, J H Mendler, J P Curfman, Y-Z Wu, M R Baer, B L Powell, J E Kolitz, J O Moore, T H Carter, R Bundschuh, R A Larson, R M Stone, K Mrózek, G Marcucci and C D Bloomfield Leukemia 2015 29: 567-575; advance online publication, September 10, 2014; 10.1038/leu.2014.267 Abstract | Full Text Hes1 suppresses acute myeloid leukemia development through FLT3 repression T Kato, M Sakata-Yanagimoto, H Nishikii, M Ueno, Y Miyake, Y Yokoyama, Y Asabe, Y Kamada, H Muto, N Obara, K Suzukawa, Y Hasegawa, I Kitabayashi, K Uchida, A Hirao, H Yagita, R Kageyama and S Chiba Leukemia 2015 29: 576-585; advance online publication, September 19, 2014; 10.1038/leu.2014.281 Abstract | Full Text CHRONIC MYELOPROLIFERATIVE NEOPLASIAS Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia A M Eiring, B D G Page, I L Kraft, C C Mason, N A Vellore, D Resetca, M S Zabriskie, T Y Zhang, J S Khorashad, A J Engar, K R Reynolds, D J Anderson, A Senina, A D Pomicter, C C Arpin, S Ahmad, W L Heaton, S K Tantravahi, A Todic, R Colaguori, R Moriggl, D J Wilson, R Baron, T O'Hare, P T Gunning and M W Deininger Leukemia 2015 29: 586-597; advance online publication, August 19, 2014; 10.1038/leu.2014.245 Abstract | Full Text CHRONIC LYMPHOCYTIC LEUKEMIA A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact A C Queirós, N Villamor, G Clot, A Martinez-Trillos, M Kulis, A Navarro, E M M Penas, S Jayne, A Majid, J Richter, A K Bergmann, J Kolarova, C Royo, N Russiñol, G Castellano, M Pinyol, S Bea, I Salaverria, M López-Guerra, D Colomer, M Aymerich, M Rozman, J Delgado, E Giné, M González-Díaz, X S Puente, R Siebert, M J S Dyer, C López-Otín, C Rozman, E Campo, A López-Guillermo and J I Martín-Subero Leukemia 2015 29: 598-605; advance online publication, August 25, 2014; 10.1038/leu.2014.252 Abstract | Full Text STEM CELLS In vitro expansion of CD34+CD38− cells under stimulation with hematopoietic growth factors on AGM-S3 cells in juvenile myelomonocytic leukemia K Sakashita, I Kato, T Daifu, S Saida, H Hiramatsu, Y Nishinaka, Y Ebihara, F Ma, K Matsuda, S Saito, K Hirabayashi, T Kurata, L T N Uyen, Y Nakazawa, K Tsuji, T Heike, T Nakahata and K Koike Leukemia 2015 29: 606-614; advance online publication, August 8, 2014; 10.1038/leu.2014.239 Abstract | Full Text FHL2 regulates hematopoietic stem cell functions under stress conditions Y Hou, X Wang, L Li, R Fan, J Chen, T Zhu, W Li, Y Jiang, N Mittal, W Wu, D Peace and Z Qian Leukemia 2015 29: 615-624; advance online publication, September 2, 2014; 10.1038/leu.2014.254 Abstract | Full Text CITED2-mediated human hematopoietic stem cell maintenance is critical for acute myeloid leukemia P M Korthuis, G Berger, B Bakker, M Rozenveld-Geugien, J Jaques, G de Haan, J J Schuringa, E Vellenga and H Schepers Leukemia 2015 29: 625-635; advance online publication, September 3, 2014; 10.1038/leu.2014.259 Abstract | Full Text IMMUNOLOGY Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10 Y Peng, X Chen, Q Liu, X Zhang, K Huang, L Liu, H Li, M Zhou, F Huang, Z Fan, J Sun, Q Liu, M Ke, X Li, Q Zhang and A P Xiang Leukemia 2015 29: 636-646; advance online publication, July 18, 2014; 10.1038/leu.2014.225 Abstract | Full Text Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy C Berlin, D J Kowalewski, H Schuster, N Mirza, S Walz, M Handel, B Schmid-Horch, H R Salih, L Kanz, H-G Rammensee, S Stevanović and J S Stickel Leukemia 2015 29: 647-659; advance online publication, August 5, 2014; 10.1038/leu.2014.233 Abstract | Full Text SENSITIVITY AND RESISTANCE TO THERAPY WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups M-T Krauth, T Alpermann, U Bacher, C Eder, F Dicker, M Ulke, S Kuznia, N Nadarajah, W Kern, C Haferlach, T Haferlach and S Schnittger Leukemia 2015 29: 660-667; advance online publication, August 11, 2014; 10.1038/leu.2014.243 Abstract | Full Text LYMPHOMA Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study H R Junlén, S Peterson, E Kimby, S Lockmer, O Lindén, H Nilsson-Ehle, M Erlanson, H Hagberg, A Rådlund, O Hagberg and B E Wahlin Leukemia 2015 29: 668-676; advance online publication, August 25, 2014; 10.1038/leu.2014.251 Abstract | Full Text The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing I Vater, M Montesinos-Rongen, M Schlesner, A Haake, F Purschke, R Sprute, N Mettenmeyer, I Nazzal, I Nagel, J Gutwein, J Richter, I Buchhalter, R B Russell, O D Wiestler, R Eils, M Deckert and R Siebert Leukemia 2015 29: 677-685; advance online publication, September 5, 2014; 10.1038/leu.2014.264 Abstract | Full Text Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party A Tanase, N Schmitz, H Stein, A Boumendil, H Finel, L Castagna, D Blaise, N Milpied, G Sucak, A Sureda, K Thomson, E Vandenberghe, A Vitek and P Dreger on behalf of the Lymphoma Working Party of the EBMT Leukemia 2015 29: 686-688; advance online publication, September 19, 2014; 10.1038/leu.2014.280 Abstract | Full Text MYELOMA Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival S Ferrero, M Ladetto, D Drandi, F Cavallo, E Genuardi, M Urbano, S Caltagirone, M Grasso, F Rossini, T Guglielmelli, C Cangialosi, A M Liberati, V Callea, T Carovita, C Crippa, L De Rosa, F Pisani, A P Falcone, P Pregno, S Oliva, C Terragna, P Musto, R Passera, M Boccadoro and A Palumbo Leukemia 2015 29: 689-695; advance online publication, July 16, 2014; 10.1038/leu.2014.219 Abstract | Full Text Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma J S Waizenegger, I Ben-Batalla, N Weinhold, T Meissner, M Wroblewski, M Janning, K Riecken, M Binder, D Atanackovic, H Taipaleenmaeki, D Schewe, S Sawall, V Gensch, M Cubas-Cordova, A Seckinger, W Fiedler, E Hesse, N Kröger, B Fehse, D Hose, B Klein, M S Raab, K Pantel, C Bokemeyer and S Loges Leukemia 2015 29: 696-704; advance online publication, August 8, 2014; 10.1038/leu.2014.236 Abstract | Full Text In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone E M Ocio, D Fernández-Lázaro, L San-Segundo, L López-Corral, L A Corchete, N C Gutiérrez, M Garayoa, T Paíno, A García-Gómez, M Delgado, J C Montero, E Díaz-Rodríguez, M V Mateos, A Pandiella, S Couto, M Wang, C C Bjorklund and J F San-Miguel Leukemia 2015 29: 705-714; advance online publication, August 8, 2014; 10.1038/leu.2014.238 Abstract | Full Text Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma Y Yang, Y Chen, M N Saha, J Chen, K Evans, L Qiu, D Reece, G A Chen and H Chang Leukemia 2015 29: 715-726; advance online publication, September 2, 2014; 10.1038/leu.2014.255 Abstract | Full Text MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib OPEN S Jagannathan, N Vad, S Vallabhapurapu, S Vallabhapurapu, K C Anderson and J J Driscoll Leukemia 2015 29: 727-738; advance online publication, September 19, 2014; 10.1038/leu.2014.279 Abstract | Full Text LETTERS TO THE EDITOR Ruxolitinib and survival improvement in patients with myelofibrosis F Passamonti, A M Vannucchi, F Cervantes, C Harrison, E Morra, H Kantarjian and S Verstovsek Leukemia 2015 29: 739-740; advance online publication, September 24, 2014; 10.1038/leu.2014.282 Full Text Reply to Passamonti et al: ruxolitinib and survival improvement in patients with myelofibrosis G Barosi and R P Gale Leukemia 2015 29: 740; advance online publication, November 3, 2014; 10.1038/leu.2014.312 Full Text Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis OPEN A Pardanani, R A Abdelrahman, C Finke, T T Lasho, K H Begna, A Al-Kali, W J Hogan, M R Litzow, C A Hanson, R P Ketterling and A Tefferi Leukemia 2015 29: 741-744; advance online publication, November 11, 2014; 10.1038/leu.2014.306 Full Text Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibitionOPEN C Pepper, A G S Buggins, C H Jones, E J Walsby, F Forconi, G Pratt, S Devereux, F K Stevenson and C Fegan Leukemia 2015 29: 744-747; advance online publication, October 28, 2014; 10.1038/leu.2014.308 Full Text Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk OPEN G P Sava, H E Speedy, M C Di Bernardo, M J S Dyer, A Holroyd, N J Sunter, H Marr, L Mansouri, S Deaglio, L Karabon, I Frydecka, K Jamroziak, D Woszczyk, G Juliusson, K E Smedby, S Jayne, A Majid, Y Wang, C Dearden, A G Hall, T Mainou-Fowler, G H Jackson, G Summerfield, R J Harris, A R Pettitt, D J Allsup, J R Bailey, G Pratt, C Pepper, C Fegan, R Rosenquist, D Catovsky, J M Allan and R S Houlston Leukemia 2015 29: 748-751; advance online publication, November 3, 2014; 10.1038/leu.2014.311 Full Text Classifying ultra-high risk smoldering myeloma A J Waxman, R Mick, A L Garfall, A Cohen, D T Vogl, E A Stadtmauer and B M Weiss Leukemia 2015 29: 751-753; advance online publication, November 5, 2014; 10.1038/leu.2014.313 Full Text Cbfb deficiency results in differentiation blocks and stem/progenitor cell expansion in hematopoiesis C Q Wang, D W L Chin, J Y Chooi, W J Chng, I Taniuchi, V Tergaonkar and M Osato Leukemia 2015 29: 753-757; advance online publication, November 5, 2014; 10.1038/leu.2014.316 Full Text CORRIGENDUM Sporadic and reversible chromothripsis in chronic lymphocytic leukemia revealed by longitudinal genomic analysis L Bassaganyas, S Beà, G Escaramís, C Tornador, I Salaverria, L Zapata, O Drechsel, P G Ferreira, B Rodriguez-Santiago, J M C Tubio, A Navarro, D Martín-García, C López, A Martínez-Trillos, A López-Guillermo, M Gut, S Ossowski, C López-Otín, E Campo and X Estivill Leukemia 2015 29: 758; 10.1038/leu.2014.309 Full Text Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com  More Nature Events